Literature DB >> 8874590

Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis.

S Fredrikson1.   

Abstract

Bladder dysfunction with increased voiding frequency and incontinence is a common problem in patients with multiple sclerosis (MS). In the present study, the effect of the synthetic vasopressin analogue, desmopressin, was evaluated on the voiding frequency in 26 patients with MS suffering from socially handicapping voidings and incontinence problems during daytime. A two-week run-in observation period to establish normal voiding patterns was followed by a double-blind, placebo-controlled cross-over study with 20 micrograms intranasal desmopressin during daily activities. There was a significant decrease in the number of voidings during the 6-h period after intranasal intake of desmopressin. Side effects were well tolerated and there was no hyponatremia or hypertension registered. Intranasal desmopressin is an efficient and well-tolerated treatment of voiding problems in patients with MS during daily activities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8874590     DOI: 10.1111/j.1600-0404.1996.tb00035.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

1.  Nocturia in Patients With Multiple Sclerosis.

Authors:  Benoit Peyronnet; Lauren B Krupp; W Stuart Reynolds; Xavier Gamé; Gérard Amarenco; Jean-Nicolas Cornu; Lana Zhovtis Ryerson; Carrie Lyn Sammarco; Jonathan E Howard; Robert W Charlson; Roger R Dmochowski; Benjamin M Brucker
Journal:  Rev Urol       Date:  2019

Review 2.  Efficacy and safety of desmopressin for treatment of nocturia: a systematic review and meta-analysis of double-blinded trials.

Authors:  Huantao Zong; Chenchen Yang; Xiaoxia Peng; Yong Zhang
Journal:  Int Urol Nephrol       Date:  2011-09-07       Impact factor: 2.370

3.  Urinary nitrite excretion and urinary variables in patients with primary nocturnal frequency of micturition: effects of indomethacin suppositories.

Authors:  Noori S Al-Waili; Thia N Al-Waili; Ali N Al-Waili; Khelod Y Saloom
Journal:  World J Urol       Date:  2005-09-27       Impact factor: 4.226

4.  Autonomic Nervous System Dysfunction in Parkinson's Disease.

Authors:  Theresa A. Zesiewicz; Matthew J. Baker; Mervat Wahba; Robert A. Hauser
Journal:  Curr Treat Options Neurol       Date:  2003-03       Impact factor: 3.598

Review 5.  Management of neurogenic bladder in patients with multiple sclerosis.

Authors:  Véronique Phé; Emmanuel Chartier-Kastler; Jalesh N Panicker
Journal:  Nat Rev Urol       Date:  2016-03-31       Impact factor: 14.432

6.  Maximal bladder capacity is a positive predictor of response to desmopressin treatment in patients with MS and nocturia.

Authors:  Athanasios Zahariou; Maria Karamouti; George Karagiannis; Polyanthi Papaioannou
Journal:  Int Urol Nephrol       Date:  2007-07-03       Impact factor: 2.370

7.  Assay of Desmopressin Acetate in Nasal Spray: Development of Validated Pre Column HPLC-Fluorescence Method.

Authors:  Neeraj Upmanyu; Pawan Kumar Porwal
Journal:  Adv Pharm Bull       Date:  2017-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.